The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements

from Applied Health Economics and Health Policy at http://bit.ly/2bDC2rt on August 31, 2016 at 03:54PM Abstract The high cost of novel treatments is the major driver of negative or restricted reimbursement decisions by healthcare payers in many countries. Costly drugs can be subject to Market Access Agreements (MAAs), which are financial (Commercial Agreements [CAs]) or […]

Economic Evaluation of Three Frequently Used Gonadotrophins in Assisted Reproduction Techniques in the Management of Infertility in the Netherlands

from Applied Health Economics and Health Policy at http://bit.ly/2bIcTZK on August 31, 2016 at 03:54PM Abstract Background and Objective Subfertility represents a multidimensional problem associated with significant distress and impaired social well-being. In the Netherlands, an estimated 50,000 couples visit their general practitioner and 30,000 couples seek medical specialist care for subfertility. We conducted an […]